望月 眞弓 (モチヅキ マユミ)

Mochizuki, Mayumi

写真a

所属(所属キャンパス)

薬学部 (三田)

職名 (名誉教授授与大学名)

名誉教授 (慶應義塾大学)

 

著書 【 表示 / 非表示

  • 現代用語の基礎知識2019

    望月 眞弓, 自由国民社, 2018年11月

    担当範囲: 薬と社会

  • くすり創りの歴史

    内藤記念くすり博物館, 2018年08月

    担当範囲: 監修

  • 現代用語の基礎知識2018

    望月 眞弓, 自由国民社, 2017年11月

    担当範囲: 薬と社会

  • スタンダード薬学シリーズⅡ6 医療薬学Ⅶ 製剤化のサイエンス

    東京化学同人, 2017年10月

    担当範囲: 編集責任

  • スタンダード薬学シリーズⅡ6 医療薬学Ⅴ 薬物治療に役立つ情報

    東京化学同人, 2017年10月

    担当範囲: 編集責任

全件表示 >>

論文 【 表示 / 非表示

  • 薬局における脂質測定の機会提供の有用性に関する探索的研究

    丸山順也,中原佐彩,,富永佳子,多田紀夫,望月眞弓

    日本臨床栄養学会雑誌 (日本臨床栄養学会)  42 ( 2 ) 179 - 190 2021年06月

    研究論文(学術雑誌), 共著

  • A cross-sectional study clarifying profiles of patients with diabetes who discontinued pharmacotherapy: reasons and consequences

    Yoshiko Tominaga , Donald E. Morisky and Mayumi Mochizuki

    BMC Endocrine Disorders (BMC)  21   117 - 124 2021年

    研究論文(学術雑誌), 共著, 査読有り

     概要を見る

    Background: Although diabetes is one of the fastest increasing diseases in prevalence worldwide and demands significant medical resources, more than half of all patients with diabetes do not achieve the expected target level of blood glucose. As a potential cause of poor glycemic control, insufficient adherence to medication has long been discussed and variably studied. However, dropout from treatment as another plausible cause has not been fully examined. The aim of this study was to clarify profiles of patients with diabetes who discontinued pharmacotherapy (Discont group) by extracting reasons of their decisions and by comparing with those who continued (Cont group) in terms of the related factors to glycemic control.
    Methods: A cross-sectional, internet-based survey was conducted among Japanese with diabetes registered in a database. A self-administered questionnaire consisting of the 8-item version of the Morisky Medication Adherence Scale (MMAS-8), glycosylated haemoglobin (HbA1c) level, and demographic and disease characteristics was completed by all participants. Reasons for medication discontinuation and resumption were also received retrospectively from participants in the Discont group. To examine the risk of uncontrolled HbA1c, logistic regression analysis was conducted in each group.
    Results: In the Discont group (148 cases), older age at resumption of pharmacotherapy and current smoking habit increased the probability of uncontrolled HbA1c, whereas in the Cont group (146 cases), a familial history of diabetes and better medication adherence in MMAS-8 scores decreased the probability of uncontrolled HbA1c. A relationship between medication adherence and HbA1c level was seen in the Cont but not in the Discont group. About 70 % of those in the Discont group made their decision to terminate diabetes treatment without consulting physicians and half of them perceived their situations inappropriately.

  • Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: An approach using latent class analysis

    Anzai T., Takahashi K., Watanabe M., Mochizuki M., Murashima A.

    BMC Psychiatry (BMC Psychiatry)  20 ( 1 )  2020年03月

     概要を見る

    © 2020 The Author(s). Background: Little is known regarding the association between adverse events (AEs) and psychiatric medications administered to pregnant women in clinical trials during the pre-marketing period. This study analyzes reports of AE association with psychiatric medication administrated during pregnancy using post-marketing spontaneous reports of AE from the Japanese Adverse Drug Event Report (JADER) database and Food and Drug Administration Adverse Event Reporting System in the United States (FAERS-US). Methods: We summarized AE reports of psychiatric medication administrated during pregnancy by comparing data obtained from JADER and FAERS-US databases with medication patterns determined as classes via latent class analysis. The odds ratios (ORs) of AE reports categorized into system organ classes in which each class was compared with those without psychiatric medications. Results: The proportions of AE reports under psychiatric medication in pregnancy among all AE reports were 22.0% and 16.6% in JADER and FAERS-US, respectively. The 10,389 reports of psychiatric medication during pregnancy were classified into 11 classes. The proportion of patients receiving four or more psychiatric drugs in JADER was larger than that in FAERS-US. The maximum number of reports in combinations of AE and medication pattern in JADER was 169, for 'general disorders and administration site conditions' from the class of four or more medications (OR = 9.1), while that in FAERS-US was 1,654, for 'injury, poisoning, and procedural complications' from the class of single psychiatric medication (OR = 2.8). Conclusions: The main AE reports and associated AE differed depending on medication patterns in pregnant women taking psychiatric medication. This study may provide a prediction of AEs that are likely to be reported with each medication pattern. Our findings of the association between AE reports and medication patterns could help improve the administration of psychiatric medications during pregnancy, though further research on additional datasets is needed to clarify these results.

  • Factors contributing to the systemic clearance of infliximab with long-term administration in Japanese patients with Crohn's disease: Analysis using population pharmacokinetics


    Matsuoka K., Hamada S., Shimizu M., Nanki K., Mizuno S., Kiyohara H., Arai M., Sugimoto S., Iwao Y., Ogata H., Hisamatsu T., Nagauma M., Kanai T., Mochizuki M., Hashiguchi M.

    International journal of clinical pharmacology and therapeutics (International journal of clinical pharmacology and therapeutics)  58 ( 2 ) 89 - 102 2020年02月

    ISSN  09461965

     概要を見る

    OBJECTIVE: Crohn's disease (CD) is a chronic inflammatory gastrointestinal disease with repeated cycles of exacerbation and remission. Infliximab (IFX), a chimeric anti-TNF-α monoclonal antibody, has been widely used for the treatment of CD. However, no study in Japanese CD patients receiving continuous IFX for more than 1 year has been reported. To avoid therapeutic failure during long-term administration in Japanese CD patients, we evaluated the variable factors of IFX pharmacokinetics and the optimal trough IFX concentration at 8 weeks after administration. MATERIALS AND METHODS: Population pharmacokinetic (PPK) analysis was performed using the nonlinear mixed-effect model based on the IFX serum concentration in 832 samples from 121 patients. A one-compartment model was used to examine interindividual variability in the systemic clearance (CL) of intravenously administered IFX. RESULTS: PPK estimates (estimated value, RSE%) were total clearance (CL: 0.018 L/h, 9.1) and volumes of distribution (Vd: 7.35 L, 12.0). Interindividual variability for CL and Vd of 0.11 and 0.16, respectively, was found. Body weight, antibody to IFX (ATI), and albumin level were factors affecting the IFX CL. IFX CL was greater in the ATI-positive than in the ATI-negative group. CL was also greater in nonremission patients. There was a significant association between the predicted serum IFX trough concentration at 8 weeks and therapeutic response with long-term continuous administration (p < 0.05), with a higher concentration at 8 weeks seen in the remission group. CONCLUSION: Using these variables including body weight, ATI, and albumin level, the IFX dose could be calculated for individual CD patients to achieve the optimal therapeutic range.

  • Exploration of education and research on drug informatics

    Mochizuki M.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 4 ) 543 - 554 2020年

    ISSN  00316903

     概要を見る

    © 2020 The Pharmaceutical Society of Japan I have been exploring methods for education and research on drug information for 43 years. There are various approaches to drug informatics research, which include collecting, evaluating, and analyzing information to solve drug related problems, sometimes producing new information from experiments and clinical research. All are based on information science. Drug informatics is information science from the viewpoint of pharmaceuticals. In addition to basic pharmacology, knowledge and skills such as epidemiology, data science, computer science, mathematical statistics, and communication studies are indispensable for the development of drug informatics.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

総説・解説等 【 表示 / 非表示

  • Genomic medicine from a team approach and the role of pharmacists

    Aomori T., Mochizuki M.

    Yakugaku Zasshi (Yakugaku Zasshi)  140 ( 5 ) 649 - 650 2020年05月

    ISSN  00316903

  • The report: Promotion of social contributions of research on clinical pharmacy and pharmaceutical sciences

    Mochizuki M.

    Yakugaku Zasshi (Yakugaku Zasshi)  139 ( 3 ) 393 - 394 2019年

    ISSN  00316903

     概要を見る

    © 2019 The Pharmaceutical Society of Japan. The Science Council of Japan issued ``The report: Promotion of Social Contributions of Research on Clinical Pharmacy and Pharmaceutical Sciences'' on September 29, 2017. This report was prepared based on the analysis of current situation of the four-year doctoral course in the graduate school of pharmacy and the contents of the symposium of 137th annual meeting of the Pharmaceutical Society of Japan (PSJ), ``Pharmaceutical Sciences in the Future: The Bridge Linking between Basic and Clinical Research''. The goal of the 4-year doctoral program is to nurture the phar-macist-scientist who has both researcher mind and professionalism as a clinical pharmacist. Research on clinical pharmacy and pharmaceutical sciences is a core research area of the 4-year doctoral course, therefore its promotion is an important issue for the faculty of pharmacy. ``Research on clinical pharmacy and pharmaceutical sciences'' has to be based on various subjects and needs of the clinical site and be conducted not only at the clinical setting but also in universities, industries, research institutions and so on. Finally, the results have to be fed back to medical care and contribute to society. In this symposium, several representatives from various academic societies and one research institution which have important functions for academic interchanges, will give presentations on issues and initiatives for promoting research on clinical pharmacy and pharmaceutical sciences.

  • Sustainableな薬学図書館であるために

    望月 眞弓

    薬学図書館 63 ( 4 ) 205 - 210 2018年10月

    記事・総説・解説・論説等(学術雑誌), 単著

  • 【老年医学(上)-基礎・臨床研究の最新動向-】 高齢患者へのアプローチ 高齢者の薬物治療 Potentially Inappropriate Medicine(PIM)

    望月 眞弓, 青森 達

    日本臨床 (日本臨床)  76 ( 増刊5 ) 347 - 353 2018年06月

    記事・総説・解説・論説等(商業誌、新聞、ウェブメディア), 共著

  • 【私の処方2018】 添付文書の読み方

    望月 眞弓

    小児科臨床 (日本小児医事出版社)  71 ( 5 ) 611 - 620 2018年05月

    記事・総説・解説・論説等(商業誌、新聞、ウェブメディア), 単著

全件表示 >>

研究発表 【 表示 / 非表示

  • 医薬品安全性情報の自発報告の位置づけ 患者からの副作用報告システムの構築の経験から 経緯、現状と課題

    橋口正行、望月眞弓

    日本薬剤疫学会学術総会第24回 Page34-35(2018.10) (仙台) , 

    2018年10月

    シンポジウム・ワークショップ パネル(指名), 日本薬剤疫学会

  • 医療用医薬品添付文書の古くて新しい話

    望月 眞弓

    第38回日本臨床薬理学会 (京都) , 

    2018年07月

    公開講演,セミナー,チュートリアル,講習,講義等, 日本臨床薬理学会

  • 日本病院薬剤師会策定「医薬品情報業務の進め方2018」と私のDI業務 日本病院薬剤師会策定「医薬品情報業務の進め方2018」の概要

    望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 

    2018年06月

    シンポジウム・ワークショップ パネル(公募), 日本医薬品情報学会

  • プラセボ効果の個体間変動要因の検討のためのスタディプロトコール

    横山 由佳, 神成 はるか, 井澤 美苗, 早川 智久, 青森 達, 望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 

    2018年06月

    ポスター発表, 日本医薬品情報学会

  • 製薬会社によるデジタル化された医薬品情報の提供・利活用に関する調査

    中田 英夫, 石川 春樹, 木村 元範, 我妻 秀和, 村松 博, 望月 眞弓

    第21回日本医薬品情報学会総会・学術大会 (鈴鹿) , 

    2018年06月

    ポスター発表, 日本医薬品情報学会

全件表示 >>

競争的研究費の研究課題 【 表示 / 非表示

  • 工学的発想と臨床心理学的発想に基づく一般用医薬品添付文書の開発

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 望月 眞弓, 基盤研究(C), 補助金,  研究代表者

受賞 【 表示 / 非表示

  • 福澤賞

    望月眞弓, 2018年11月, 慶應義塾, 医薬品情報学に関する先駆的な教育・研究と学術への貢献

    受賞区分: 塾内表彰等

  • 日本医療薬学会功績賞

    2016年09月, 日本医療薬学会

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 永井記念国際女性科学者賞

    2016年06月, 日本薬剤学会

    受賞区分: 国内外の国際的学術賞

  • 日本医薬品情報学会論文賞

    橋口正行、金子梨沙、保坂藍、植田恵子、小寺典子、中村眞弓、榊原幹夫、黒川達夫、望月眞弓., 2013年08月, 日本医薬品情報学会, 一般用医薬品の添付文書理解度調査法の開発、ー理解度への影響因子の検討ー.

  • 私立薬科大学協会教育賞

    望月眞弓, 2012年03月, 私立薬科大学協会

    受賞区分: その他

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 課題研究(病院薬学)

    2019年度

  • 演習(病院薬学)

    2019年度

  • 医療系薬学特論Ⅰ

    2019年度